학술논문
Risk factors for cancer in patients with primary biliary cholangitis and autoimmune hepatitis and primary biliary cholangitis overlap syndrome
Document Type
article
Author
Michelle Harriz Braga; Guilherme Grossi Lopes Cançado; Paulo Lisboa Bittencourt; Cláudia Alves Couto; Laura Vilar Guedes; André Mourão Costa Lima; Maria Lucia Gomes Ferraz; Cristiane Alves Villela-Nogueira; Mateus Jorge Nardelli; Luciana Costa Faria; Nathalia Mota de Faria Gomes; Elze Maria Gomes Oliveira; Vivian Rotman; Maria Beatriz Oliveira; Simone Muniz Carvalho Fernandes da Cunha; Marlone Cunha-Silva; Liliana Sampaio Costa Mendes; Claudia Alexandra Pontes Ivantes; Liana Codes; Valéria Ferreira de Almeida e Borges; Fabio Heleno de Lima Pace; Mario Guimarães Pessoa; Izabelle Venturini Signorelli; Gabriela Perdomo Coral; João Galizzi Filho; Aline Lopes Chagas; Debora Raquel Benedita Terrabuio; Eduardo Luiz Rachid Cançado
Source
Annals of Hepatology, Vol 28, Iss 4, Pp 101105- (2023)
Subject
Language
English
ISSN
1665-2681
Abstract
Introduction and objectives: Primary biliary cholangitis (PBC) and autoimmune hepatitis (AIH) and PBC overlap syndrome (AIH/PBC) have been associated with a higher risk of hepatocellular carcinoma (HCC) and extra-hepatic malignancy (EHM). This study aims to assess potential risk factors associated with cancer development in PBC and AIH/PBC. Materials and methods: The Brazilian Cholestasis Study Group database was reviewed to compare clinical and laboratory features of PBC patients with HCC and EHM with those without cancer. Results: Among the 752 PBC patients enrolled, 64 of them with AIH/PBC, 87 cancers were identified in 72 patients, including 20 cases of HCC and 67 of EHM. Patients with HCC had a higher prevalence of cirrhosis (95% vs. 32.5% of those subjects without cancer, p≤0.001), smoking (55% vs. 12.3%, p≤0.001), CREST syndrome (30% vs 7.6%, p=0.003) and prior azathioprine (30% vs 8%, p= 0.005) and prednisone (35% vs 14%, p= 0.018) use, whereas patients with EHM had a higher prevalence of smoking (42.3% vs 12.4% of those subjects without cancer, p=